In STEP 1 (semaglutide 2.4 mg, 1,961 participants), most weight loss occurred by weeks 30 to 40, with the curve flattening after that
For those interested in other GLP-1 options, emerging medications like survodutide , orforglipron , and CagriSema are in various stages of development, though none currently offer the compounding flexibility needed for microdosing
J Am Board Fam Pract
Sun, H., Hao, Y., Liu, H., & Gao, F
Ozempic Use Linked to Adverse Gastrointestinal Events Study Highlight: Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss In October 2023, researchers at the University of British Columbia published findings in the Journal of the American Medical Association (JAMA), which found an increased risk of adverse gastrointestinal events associated with GLP-1 receptor agonists used for weight loss